利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.033 秒)

    Nitroxyl Progenitors in the Treatment of Heart Failure
    3.
    发明申请
    Nitroxyl Progenitors in the Treatment of Heart Failure 审中-公开
    硝酸基因祖细胞治疗心力衰竭

    公开(公告)号：US20110081427A1

    公开(公告)日：2011-04-07

    申请号：US12949533

    申请日：2010-11-18

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A61K33/00 ,  A61P9/04 ,  A61K31/655

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

    摘要翻译： 施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。 此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。 另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。 此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

    Nitroxyl progenitors in the treatment of heart failure
    4.
    发明授权
    Nitroxyl progenitors in the treatment of heart failure 有权
    硝基脯氨酸治疗心力衰竭

    公开(公告)号：US07863262B2

    公开(公告)日：2011-01-04

    申请号：US11096924

    申请日：2005-03-31

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A01N51/00 ,  A61K31/655 ,  A61K31/13 ,  A61K33/26

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO(Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.

    摘要翻译： 施用HNO / NO供体化合物，例如Angeli盐可增加心肌收缩力，同时降低心衰患者的左心室预负荷。 此外，HNO / NO供体化合物异丙胺（IPA）/ NO（Na（CH 3）2 CHNHN（O）NO）的给药令人惊讶地在经历心力衰竭的受试者中表现出优于HNO / NO- 捐赠化合物Angeli的盐。 另外，与使用NO-供体观察到的效果相反，将HNO / NO供体与正性肌力药物联合给药不会损害正性肌力药物的正性肌力作用。 此外，HNO / NO-不依赖于肾上腺素能系统发挥其正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也能增加收缩力。

    Nitroxyl progenitors in the treatment of heart failure
    5.
    发明授权
    Nitroxyl progenitors in the treatment of heart failure 有权
    硝基脯氨酸治疗心力衰竭

    公开(公告)号：US06936639B2

    公开(公告)日：2005-08-30

    申请号：US10226412

    申请日：2002-08-21

    申请人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    发明人： David A. Wink ,  Martin Feelisch ,  David A. Kass ,  Nazareno Paolocci ,  Katrina Miranda ,  Jon Fukuto ,  Tatsuo Katori

    IPC分类号： A61K31/13 ,  A61K31/16 ,  A61K31/19

    CPC分类号： A61K31/655 ,  A61K31/13 ,  A61K31/16 ,  A61K33/00 ,  A61K2300/00

    摘要： Administration of an HNO/NO− donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure Moreover, administration of the HNO/NO− donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO− donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO− donors, administration of an HNO/NO− donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent Further, HNO/NO− exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy

    摘要翻译： 施用HNO / NO - 辅助化合物如Angeli盐可增加心肌收缩力，同时降低经历心力衰竭的受试者的左心室预负荷。此外，给予HNO / 供体化合物异丙胺（IPA）/ NO（Na（CH 3 3）2 CHNHN（O）NO）令人惊讶地在经历心力衰竭的受试者中表现出正性肌力作用 由HNO / NO - 捐赠化合物Angeli的盐引起的那些。 另外，与使用NO-SUP供体观察到的效果相反，将HNO / NO + - 供体与正性肌力药物组合给药不会损害正性肌力作用 正性肌力药物另外，HNO / NO 发挥其与肾上腺素能系统无关的正性肌力作用，即使在接受β-拮抗剂治疗的受试者中也增加收缩力

    Thiol-Sensitive Positive Inotropes
    6.
    发明申请
    Thiol-Sensitive Positive Inotropes 审中-公开
    硫醇敏感正性Inotropes

    公开(公告)号：US20090298795A1

    公开(公告)日：2009-12-03

    申请号：US11922793

    申请日：2006-06-23

    申请人： Nazareno Paolocci ,  David A. Kass ,  Carlo G. Tocchetti

    发明人： Nazareno Paolocci ,  David A. Kass ,  Carlo G. Tocchetti

    IPC分类号： A61K31/655 ,  A61K31/18

    CPC分类号： A61K33/00 ,  A61K31/13 ,  A61K31/135 ,  A61K31/185 ,  A61K31/655 ,  C12Q1/6818

    摘要： The present invention relates to methods for treating diastolic dysfunction or a disease, disorder or condition associated with diastolic dysfunction, methods for treating heart failure, methods for modulating SR Ca2+ release and/or uptake, methods for enhancing myocyte relaxation, preload or E2P hydrolysis, and methods for treating ventricular hypertrophy.

    摘要翻译： 本发明涉及用于治疗舒张功能障碍或与舒张功能障碍相关的疾病，病症或病症的方法，用于治疗心力衰竭的方法，用于调节SR Ca 2+释放和/或摄取的方法，用于增强肌细胞松弛，预加载或E2P水解的方法， 和治疗心室肥大的方法。

    Beta 3-Adrenoreceptor Agonists for the Treatment of Cardiac Hypertrophy and Heart Failure
    8.
    发明申请
    Beta 3-Adrenoreceptor Agonists for the Treatment of Cardiac Hypertrophy and Heart Failure 审中-公开
    β3肾上腺素受体激动剂治疗心脏肥大和心力衰竭

    公开(公告)号：US20110263668A1

    公开(公告)日：2011-10-27

    申请号：US12828642

    申请日：2010-07-01

    申请人： Lili Ayala Barouch ,  David A. Kass ,  An L. Moens

    发明人： Lili Ayala Barouch ,  David A. Kass ,  An L. Moens

    IPC分类号： A61K31/4178 ,  A61K31/196 ,  A61K31/404 ,  A61K31/353 ,  A61P31/04 ,  A61P9/12 ,  A61P3/10 ,  A61P3/06 ,  A61P7/04 ,  A61P7/02 ,  A61K31/24 ,  A61P9/00

    CPC分类号： A61K31/196 ,  A61K31/24 ,  A61K31/353 ,  A61K31/404 ,  A61K31/4178

    摘要： The present invention relates to the field of cardiology. More specifically, the present invention relates to the use of β3 adrenoreceptor agonists to treat cardiac hypertrophy and heart failure. In a specific embodiment, a method for treating cardiac hypertrophy comprises the step of administering a therapeutically effective amount of a β3 adrenoreceptor agonist to a patient diagnosed with cardiac hypertrophy. In a more specific embodiment, the method for treating cardiac hypertrophy comprises the step of administering a therapeutically effective amount of the β3 adrenoreceptor agonist BRL 26830A to a patient diagnosed with cardiac hypertrophy. In a further embodiment, the present invention provides a method for treating a cardiovascular disease or condition associated with cardiac hypertrophy comprising the step of administering a therapeutically effective amount of a β3 adrenoreceptor agonist to a patient diagnosed with cardiac hypertrophy.

    摘要翻译： 本发明涉及心脏病学领域。 更具体地，本发明涉及用于治疗心脏肥大和心力衰竭的3肾上腺素受体激动剂的用途。 在具体实施方案中，治疗心脏肥大的方法包括向诊断患有心脏肥大的患者施用治疗有效量的“肾上腺素受体激动剂”的步骤。 在更具体的实施方案中，治疗心脏肥大的方法包括向诊断为心脏肥大的患者施用治疗有效量的3肾上腺素受体激动剂BRL 26830A的步骤。 在另一个实施方案中，本发明提供了治疗与心脏肥大相关的心血管疾病或病症的方法，包括向诊断患有心脏肥大的患者施用治疗有效量的“肾上腺素受体激动剂”的步骤。

    Assessing cardiac contractility and cardiovascular interaction
    9.
    发明授权
    Assessing cardiac contractility and cardiovascular interaction 失效
    评估心脏收缩力和心血管相互作用

    公开(公告)号：US6090047A

    公开(公告)日：2000-07-18

    申请号：US962847

    申请日：1997-11-03

    申请人： David A. Kass ,  Hideaki Senzaki ,  Chen-Huan Chen

    发明人： David A. Kass ,  Hideaki Senzaki ,  Chen-Huan Chen

    IPC分类号： A61B5/029 ,  G06F17/00 ,  A61N5/00

    CPC分类号： A61B5/0215 ,  A61B5/02028 ,  A61B5/029 ,  A61B5/0456 ,  A61B8/06

    摘要： A novel method for estimating the end-systolic pressure-volume relationship (ESPVR) is presented. The method provides for accurate estimation of the ESPVR from a single beat of the cardiac cycle. The method is based on normalized human time varying elastance curves [E.sub.N (t.sub.N)]. The ESPVR is estimated from one beat using PV data measured at normalized time t.sub.N and end-systole (t.sub.max) to predict intercept: ##EQU1## and slope: E.sub.max(SB) =P(t.sub.max)/[V(t.sub.max)-V.sub.0(SB) ]. The present invention provides a method for ESPVR estimation which is non-invasive and particularly applicable for bedside applications.

    摘要翻译： 提出了一种估计收缩末期压力 - 体积关系（ESPVR）的新方法。 该方法提供了从心动周期的单个搏动精确估计ESPVR。 该方法基于归一化的人类时变弹性曲线[EN（tN）]。 使用在标准化时间tN和终点收缩期（tmax）测量的PV数据来估计ESPVR，以预测截距：斜率：Emax（SB）= P（tmax）/ [V（tmax）-V0（SB）] 。 本发明提供一种非侵入性的ESPVR估计方法，特别适用于床边应用。